ConCallIQ
Go Pro
AJANTPHARM Diversified 30 Jan 2024

Ajanta Pharma Limited — Q3 FY24

Ajanta Pharma reported a strong Q3 FY24 with consolidated revenue of INR 1,105 crore, up 14% YoY, driven by broad-based growth across branded generics.

bullish high
Compare with...
Revenue ₹1,105 Cr +14%
EBITDA ₹314 Cr
PAT ₹210 Cr
EBITDA Margin 28%
Duration
Read Time 1 min read

Financial stats pending filing verification

Risk Intelligence

Material risks this quarter

Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.

Risks

R

Red Sea crisis impacting freight costs and transit times

Freight costs may increase by ~0.5% of revenue (~INR 30-35 crore) and transit times by 15-20 days, potentially pressuring margins and working capital.

medium · management_commentary
R

US price erosion remains an unknown variable

While current price erosion is stable at high single digits, any acceleration could impact US generics profitability and overall margins.

high · management_commentary
R

Unpredictability of Africa institutional business

Institutional business is lumpy and dependent on agency funding and malaria season, making it difficult to forecast.

medium · management_commentary
R

NLEM price revisions impacting India cardiology growth

Cardiology growth was lower than IPM due to price revision in a major product in December 2022, and competitive intensity has increased.

medium · analyst_question